Thank you for your message!
We will get in touch with you soon.
Our vision: To challenge paradigms by developing effective innovations that treat disease and optimize health, and that prove their value in methodologically sound scientific research.
Hamburg, Oktober 28, 2024
Hamburg, August 27, 2024
Great news: The results of the ELAINE study, published in Epilepsia Open, confirm the positive impact of our digital therapy...
Continue readingHamburg, June 17, 2024
GAIA CEO, Dr. Mario Weiss sits down with The Pharma Letter’s Guy Martin for an in-depth interview to explore the...
Continue readingHamburg / München, May 28, 2024
Nach einer langjährigen erfolgreichen Partnerschaft geben Servier Deutschland und GAIA bekannt, dass die Vermarktungsrechte für deprexis® ab 1. Juni 2024...
Continue readingHamburg, March 5, 2024
Hamburg, 19. Januar 2024
Mit „Lamont“ startet ab sofort eine randomisierte kontrollierte Studie (RCT), die sich an Patient:innen mit Multipler Sklerose (MS) richtet. Die...
Continue readingHamburg, Dezember 2023
Unter dem Motto „Ökologische Psychiatrie und Psychotherapie” warf der diesjährige DGPPN Kongress ein Schlaglicht auf die aktuellen und zukünftigen klimawandelbedingten...
Continue readingHamburg, Mittwoch 27. September 2023
Hamburg/ Frankfurt, Mittwoch 10. Mai 2023 10.00 CEST
Hamburg, Montag 24. April 2023 14.00 CEST
Ab sofort stellt die HanseMerkur ihren Krankenvollversicherten, die unter Angststörungen oder Multipler Sklerose (MS) mit Erschöpfungs- und Ermüdungszuständen (Fatigue) leiden,...
Continue readingHamburg, Dienstag 07. März 2023 9.00 CEST
Hamburg, Montag 06. März 2023 11.00 CEST
Hamburg, Dienstag 10. Januar 2023 15.00 CEST
Hamburg, Mittwoch 14. Juli 2022 12.30 CEST
Im Rahmen ihrer Brustkrebsbehandlung befinden sich die Patientinnen in einer emotionalen Achterbahnfahrt: Neben dem Gefühl, endlich ein neues, gesundes Leben...
Continue readingUppsala, Sweden and Hamburg, Germany, Wednesday 13. July 2022 15.30 CEST
Orexo, GAIA’s partner for the commercialization of deprexis®, GAIA’s evidence-based digital therapy for the treatment of symptoms of depression, announced...
Continue readingStockholm, Sweden, Tuesday 03. May 2022 11.29 CEST
In this trial, GAIA combined its digital therapeutic software platform with smart sensors, including a sensorized shirt that collects biomedical...
Continue readingHamburg, Germany, Donnerstag 14 April 2022 15.00 CEST
elevida, die aus dem Hause GAIA stammende Digitale Gesundheitsanwendung gegen Fatigue bei MS ist die bisher einzige Digitale Gesundheitsanwendung für...
Continue readingHamburg, Germany, Freitag 01 April 2022 17.00 CEST
Hamburg, 01.04.2022 - Als erste Digitale Gesundheitsanwendung (DiGA) bei Angst- und Panikstörungen wurde velibra bereits im Oktober 2020 in das...
Continue readingHamburg, Germany, Monday 15 November 2021 10.00 CEST
GAIA CEO, Dr. Mario Weiss sits down with ZS.com’s Lukas Grabner for a one-on-one interview about the successful development and...
Continue readingHamburg, Germany, Tuesday 02 November 2021 10.00 CEST
In a collaboration with Deloitte, GAIA released an extensive publication on the evolution and future of Digital Therapeutics.
Continue readingBern, Switzerland, Wednesday 15 Sep 2021 10.00 CEST
GAIA’s long-time research and development partner Prof. Dr. Thomas Berger is the 2021 recipient of the coveted “Swiss Nobel Prize”...
Continue readingHamburg, Germany, Montag 31 Mai 2021 10.00 CEST
GAIA AG today announced the appointment of Andreas Bertram as Chief Operating Officer. Andreas brings with him more than 25...
Continue readingHamburg, Germany, Montag 10 Mai 2021 10.00 CEST
Die von GAIA entwickelte digitale Gesundheitsanwendung (DiGA) vorvida®, ist letzte Woche in das DiGA-Verzeichnis des Bundesinstituts für Arzneimittel und Medizinprodukte...
Continue readingHamburg, Germany, Monday 03 May 2021 10.00 CEST
Stan Sugarman to join the Leadership Team and invest in GAIA AG.
Continue readingHamburg, Germany, Monday 04 January 2021 10.00 CEST
GAIA’s research project „Nevermind“ is published in the official „Success Story Yearbook 2020“ as one of nine EU funded projects...
Continue readingAmsterdam, Netherlands, Wednesday 23 September 2020 10.00 CEST
According to a newly published observational study, GAIA’s digital therapeutic deprexis is effective in real-world routine medical care. These findings...
Continue readingBielefeld, Germany, Tuesday 23 June 2020 10.00 CEST
In the largest ever health economic evaluation of a digital therapeutic, researchers at the University Bielefeld found that GAIA’s deprexis...
Continue readingOxford, UK, Thursday 06 June 2020 10.00 CEST
The largest study to date on combining routine psychotherapy with digital therapeutics confirmed that adding GAIA’s deprexis significantly boosts treatment...
Continue readingHamburg, Germany, Thursday 06 February 2020 10.00 CEST
GAIA AG, one of the first developers of digital therapeutics worldwide, announces its successful certification by TÜV Rheinland, an independent...
Continue readingCambridge, UK, Thursday 30 January 2020 10.00 CEST
GAIA’s digital therapy reliably reduces depression symptoms over 8 to 12 weeks, according to a newly published meta-analysis. The researchers...
Continue readingHamburg, Tuesday 03 December 2019 12.00 CEST
The DAK-Gesundheit, one of Germany’s top insurance providers, released a report last week on the topic of depression among teens...
Continue readingToronto, Monday 04 November 2019 12.00 CEST
A randomized controlled trial (RCT) showed that adding GAIA’s digital therapy software, deprexis, to standard inpatient hospital treatment improved remission...
Continue readingHamburg, Friday 27 September 2019 12.00 CEST
September is #PainAwarenessMonth, a topic we’re glad to see being supported in social media. Chronic pain and the management of...
Continue readingBielefeld, Tuesday 04 June 2019 17.00 CEST
A newly published study once again confirmed the cost-saving effects of GAIA’s digital therapies. Specifically, health economic data were analyzed...
Continue readingHamburg, Tuesday 02 April 2019 17.00 CEST
GAIA’s fully automated digital therapeutic, vorvida, reduces risky drinking patterns in adults with alcohol addiction, according to a new randomized...
Continue readingHamburg, Friday 22 March 2019 16.00 CEST
GAIA’s Prostana® Reports Positive Signs from Both Urologists and Patients in an Interim Analysis
Continue readingHamburg, Monday 04 February 2019 16.00 CEST
A recently published RCT demonstrates GAIA AG has once again created a clinically effective digital therapy intervention, this time with...
Continue readingCastrop-Rauxel, Thursday 17 January 2019 13.00 CEST
A new randomized controlled trial has confirmed that adding GAIA’s depression software deprexis significantly boosts treatment effectiveness. Inpatients at a...
Continue readingHamburg, Monday 10 December 2018 13.00 CEST
Over the past decade, GAIA’s research and development has focused on digital treatments based on artificial intelligence (AI) to improve...
Continue readingHamburg, Tuesday 18 September 2018 11.00 CEST
A high number of inpatient cases, hospitalization days and physician visits bloat healthcare spending without necessarily improving the quality of...
Continue readingHamburg, Wednesday 25 July 2018 11.30 CEST
A randomized controlled trial (RCT) of Emyna with 200 people living with epilepsy has shown very encouraging results.
Continue readingHamburg, Wednesday 13 June 2018 13.00 CEST
Significant reduction in gambling-related symptoms have been recorded following treatment with GAIA’s therapeutic software. Researchers from the University Medical Center...
Continue readingBerlin, Monday 04 June 2018 12.00 CEST
Behavioral change is crucial for treating back pain. This message lies at the heart of our CEO’s presentation this Wednesday,...
Continue readingHamburg, Friday 18 May 2018 18.00 CEST
Can GAIA’s evidence-based therapy software improve the effectiveness of routine behavioral therapy? Yes! And a randomized controlled trial (RCT) has...
Continue readingRio de Janeiro, Friday 13 April 2018 11.00 BRT
Deprexis has launched in Brazil! Deprexis is a fully-automated therapy for individuals suffering from depressive disorders.
Continue readingHamburg, Tuesday 27 March 2018 09.00 GMT
GAIA’s fully automated therapy software, Elevida, reduces Multiple Sclerosis (MS) related fatigue in patients, a randomized controlled trial (RCT) has...
Continue readingBerlin, Thursday 15 March 2018 11.45 GMT
Our partnership with DAK Gesundheit, a leading German health insurer, has been extended with the launch of Rücken@Fit.
Hamburg, Thursday 22 February 2018 09.15 CET
A recent meta-analysis reveals that beyond clever marketing, several guided internet-based interventions fail to deliver cost effectiveness. Thus, it...
Continue readingDubai, Tuesday 30 January 2018 17.35 CET
The United Arab Emirates (UAE) will now use deprexis MS, GAIA’s digital therapy software, to treat depression in multiple sclerosis...
Continue readingMunich, Monday 15 January 2018 06.35 CET
A randomized controlled trial (RCT) has provided powerful evidence that adding our digital software significantly improves inpatient treatment efficacy. This...
Continue readingSan Francisco, Tuesday 02 January 2018 10.00 PST
GAIA AG will present at the 2018 Biotech Showcase ™ to be held January 8 – 10 at the Hilton...
Continue readingBerlin, Friday 15 December 2017 09.05 GMT
Can digital therapeutic interventions empower multiple sclerosis (MS) patients to better cope with symptom flare-ups? Can digital therapy software help...
Continue readingGlasgow, UK, Thursday 30 November 2017 07.25 GMT
A new study confirms that deprexis® reduces total health insurance costs. GAIA’s leading digital therapy software is proven to facilitate...
Continue readingHamburg, Thursday 29 November 2017 06.35 GMT
Leading German news programme, Tagesschau has showcased consumer testimony highlighting the immense help GAIA’s fully automated therapy software is for...
Continue readingHamburg, Wednesday 16 August 2017 10.22 CST
Digital therapy is radically reshaping the healthcare landscape for a number of key reasons: Well-developed digital therapeutics can be as...
Continue readingOxford, UK, Friday 28 July 2017 11.09 GMT
A meta-analysis of GAIA’s digital therapy for depression (deprexis) has been published in the latest issue of the peer-reviewed scientific...
Continue readingExeter, UK, Wednesday 19 July 2017 14:19 GMT
In a new article coming out in Behaviour Research and Therapy, a team of leading researchers reported that one of...
Continue readingBerlin, Thursday 20 April 2017 11.43 CST
Two GAIA-chaired symposia have been accepted by the Scientific Programme Committee of the World Congress of Psychiatry, to be held...
Continue readingBerlin, Tuesday 18 April 2017 15.45 CST
Optimizing physicians’ prescription behavior in ambulatory care settings can be a challenge – particularly if the physicians are working in...
Continue readingAustin, Texas, Friday 24 February 2017 13.36 CST
A randomized controlled trial with N = 376 depressed adults, published in the latest issue of the Journal of Consulting...
Continue readingAmsterdam, Wednesday 22 February 2017 17.45 GMT
A new meta-analysis of individual patient data, published in the latest issue of JAMA Psychiatry, confirmed the efficacy of deprexis...
Continue readingHamburg, Tuesday 14 February 2017 18.00 GMT
Servier, the independent international pharmaceutical company, and GAIA, a global pioneer in digital therapy, have signed a partnership to extend...
Continue readingBerlin, Friday 27 January 2017 17.00 GMT
A randomized controlled trial examined whether experienced psychotherapists can use one of GAIA’s interventions (Deprexis) to augment or enhance their...
Continue readingSan Francisco, Thursday 5 January 2017 15.00 GMT
We are pleased to announce that Gaia AG will present at the Digital Medicine Showcase 2017, as part of...
Continue readingHamburg, Wednesday 4 January 2017 10.00 GMT
GAIA has contributed a chapter on internet-based interventions for work-related mental disorders, which was recently published in the book “Arbeitsplatzbezogene...
Continue readingAustin, Texas, Monday 12 December 2016 18.30 GMT
A randomized controlled trial with N = 376 adults with at least moderately severe depression has confirmed that Deprexis is...
Continue readingHamburg, Friday 9 December 2016 14.30 GMT
A randomized controlled trial testing the efficacy of vorvida, our intervention for adults trying to reduce excessive alcohol consumption, has...
Continue readingHamburg, Tuesday 6 December 2016 9.00 GMT
Mario Weiss (CEO GAIA) and Michael Nick ( EVP Business Development) will attend the 35th annual JP Morgan Healthcare Conference...
Continue readingHamburg, Friday 2 December 2016 11.15 GMT
Elevida, our cognitive-behavioural therapy software for patients with multiple sclerosis has been demonstrated to be effective in a randomized controlled...
Continue readingZurich, Thursday 10 November 2016 16.00 GMT
The Sanitas health insurance, covering almost 10% of the Swiss population, has been awarded the Innovation Award 2016 of the...
Continue readingBern, Monday 12 September 2016 10.00 GMT
After nearly four years of research and development, we are proud to announce that velibra, our digital therapy software for...
Continue readingHamburg, Monday 15 August 2016 11.30 GMT
The French pharma company and GAIA entered into a marketing and sales cooperation for deprexis in Germany. Servier will promote...
Continue readingHamburg, Saturday 30 April 2016 12.30 GMT
Veovita and the DAK-G statutory health insurance today reached an agreement that will help thousands of people getting faster and...
Continue readingHamburg, Thursday 21 January 2016 10.30 GMT
Deprexis in Italian and Portuguese: Deprexis is now available in Italian and Portuguese/Brazilian. These newly translated were developed by GAIA...
Continue readingZurich, Saturday 12 December 2015 09.30 GMT
GAIA and the Swiss statutory health insurance today signed a comprehensive cooperation agreement that will help Sanitas to leverage the...
Continue readingWe will get in touch with you soon.